Christopher D Barrett
Overview
Explore the profile of Christopher D Barrett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore H, Barrett C
J Thromb Haemost
. 2025 Mar;
23(3):1120-1122.
PMID: 40057369
No abstract available.
2.
3.
A Novel Fibrinolysis Resistance Capacity Assay Can Detect Fibrinolytic Phenotypes in Trauma Patients
Barrett C, Suzuki Y, Moore E, Moore H, Maginot E, White C, et al.
Thromb Haemost
. 2025 Jan;
PMID: 39837554
Background: To evaluate residual fibrinolysis resistance activity (FRA) in plasma, a detergent-modified plasma clot lysis assay time (dPCLT) was established in which α2-antiplasmin (A2AP) and plasminogen activator inhibitor type 1...
4.
Maginot E, Moore H, Moore E, Bernhardt I, Moody T, White C, et al.
J Trauma Acute Care Surg
. 2025 Jan;
PMID: 39836091
Background: Tissue-plasminogen activator-challenged thromboelastography (tPA-TEG) predicts massive transfusion and mortality better than conventional rapid thromboelastography (rTEG), with little concordance between their lysis values (LY30). We hypothesized that the main fibrinolytic...
5.
Sharma D, Thomas S, Moody T, Taylor M, Ituarte B, Georgeson C, et al.
Thromb J
. 2024 Nov;
22(1):101.
PMID: 39533305
Inflammatory dermatologic diseases have long been viewed as a "skin limited" disease process. Current literature on inflammatory dermatologic diseases investigates their relationship and influence on thromboembolic states and thromboembolic complications...
6.
Sharma D, Barrett C, Moore H, Jackson J, Sandberg T, Gawargi F, et al.
J Thromb Haemost
. 2024 Sep;
22(12):3640-3644.
PMID: 39299613
No abstract available.
7.
Barrett C, Moore P, Moore E, Moore H, Chandler J, Siddiqui H, et al.
Chest
. 2024 May;
167(1):67-75.
PMID: 38710463
Background: Complex pleural space infections often require treatment with multiple doses of intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease, with treatment failure frequently necessitating surgery. Pleural infections are rich in...
8.
Barrett C, Neal M, Schoenecker J, Medcalf R, Myles P
Transfusion
. 2024 Mar;
64 Suppl 2:S11-S13.
PMID: 38461482
Tranexamic acid (TXA) has proven mortality benefit if used early after traumatic injury, likely related to a combination of bleeding reduction and other non-bleeding effects. If TXA is given more...
9.
Moore H, Barrett C, Moore E, Pieracci F, Sauaia A
J Am Coll Surg
. 2024 Feb;
239(1):30-41.
PMID: 38299576
Background: Conventional rapid thrombelastography (rTEG) cannot differentiate fibrinolysis shutdown from hypofibrinolysis, as both of these patient populations have low fibrinolytic activity. Tissue plasminogen activator (tPA) TEG can identify depletion of...
10.
Barrett C, Moore H, Moore E, Chandler J, Sauaia A
Blood Coagul Fibrinolysis
. 2023 Nov;
34(8):499-507.
PMID: 37942744
Introduction: Venous thromboembolism (VTE) remains a significant source of postinjury morbidity and mortality. Beta-hydroxy beta-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (rosuvastatin) significantly reduced pathologic clotting events in healthy populations in a prior...